Nebulized flunisolide in infants and young children with asthma: a pilot study.

Abstract

The role of nebulized flunisolide solution in controlling recurrent respiratory symptoms was assessed in a double-blind placebo-controlled parallel study on 23 infants and small children (mean age, 14.2 months) with bronchial asthma. Five of the 12 children in the placebo group and 1 of the 11 patients on active treatment had to be withdrawn from the study. Flunisolide significantly improved symptom scores of wheezing and cough. The rescue treatments with salbutamol did not differ between the two groups during the study. Parents considered the active treatment effective in all the patients, while the placebo was considered useful in 4 of 7 children. No side effects were detected with either treatments. This study indicates that nebulized flunisolide may be an effective treatment for infants with recurrent wheezing and cough.

• Authors: F M de Benedictis, L C Martinati, L F Solinas, G Tuteri, A L Boner
• Journal: Pediatric pulmonology (Pediatr Pulmonol) Vol. 21 Issue 5 Pg. 310-5 (May 1996) ISSN: 8755-6863 [Print] United States
• PMID: 8726156 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• Bronchodilator Agents
• Fluocinolone Acetonide
• flunisolide
• Ipratropium
• Albuterol

Topics

• Airway Resistance (drug effects)
• Albuterol (administration & dosage, adverse effects)
• Anti-Inflammatory Agents (administration & dosage, adverse effects)
• Asthma (drug therapy)
• Bronchodilator Agents (administration & dosage, adverse effects)
• Child, Preschool
• Double-Blind Method
• Female
• Fluocinolone Acetonide (administration & dosage, adverse effects, analogs & derivatives)
• Humans
• Infant
• Ipratropium (administration & dosage, adverse effects)
• Male
• Nebulizers and Vaporizers
• Treatment Outcome